Medtronic Slips 0.08% on 33% Volume Drop Ranks 215th in U.S. Trading Activity

Medtronic (MDT) closed September 26, 2025, with a 0.08% decline to $145.32, trading on $480 million volume—a 32.97% drop from the previous day's turnover. The stock ranked 215th in trading activity among U.S. equities, reflecting muted investor engagement despite its position as a global medical device leader.

Recent regulatory filings highlighted a 15% increase in R&D expenditures year-to-date, driven by expanded trials for its next-gen spinal fusion systems. The company also announced a partnership with three European hospitals to pilot AI-driven surgical robotics, though no financial terms were disclosed. Analysts noted the move could accelerate product differentiation in a competitive market.

Shareholder communications revealed a $250 million share repurchase authorization, with $180 million executed in Q3 2025. The buyback pace aligns with the firm's 5-year $10 billion capital return program. Institutional ownership dipped 0.7% in the latest quarter, according to a filing, as underperforming peers in the healthcare sector saw higher redemption rates.

To produce a statistically-sound back-test I need to be sure we’re modelling your idea exactly the way you have in mind. Could you please confirm a few details? Market universe: Am I correct that you want to scan the entire U.S. stock market (all common shares listed on NYSE + NASDAQ + NYSE-Arca) each day and pick the 500 names with the highest $-trading volume for that particular day? Or do you already have a fixed list of 500 tickers you’d like to use? Trade mechanics: Entry price: should we assume we buy at that day’s close (after we know the volume ranking) and exit the following day’s close? Or do you prefer buy at next day’s open and sell at the close of the same day? Any transaction-cost or slippage assumption you’d like me to include? Re-balancing frequency: The instruction “holds them for 1 day” suggests we repeat the screen and re-balance every trading day – please confirm. Benchmark / performance output: Do you want raw strategy equity-curve & stats, or also performance versus a benchmark (e.g., SPY)? Once these points are clear I can set up the data retrieval and run the back-test.